

FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2021

MIRADA MEDICAL LIMITED

MENZIES

MIRADA MEDICAL LIMITED

COMPANY INFORMATION

Directors

H Bettesworth
J T De Vries (appointed 29 September 2021)
S J C Gray
S G B Jantet
E Saragnese

Registered number

06515901

Registered office

New Barclay House
234 Botley Road
Oxford
Oxfordshire
OX2 0HP

Independent auditor

Menzies LLP
Chartered Accountants & Statutory Auditor
1st Floor
Midas House
62 Goldsworth Road
Woking
Surrey
GU21 6LQ

MIRADA MEDICAL LIMITED

CONTENTS

	Page
Consolidated Statement of Financial Position	1 - 2
Company Statement of Financial Position	3 - 4
Consolidated Statement of Changes in Equity	5
Company Statement of Changes in Equity	6
Notes to the Financial Statements	7 - 17

MIRADA MEDICAL LIMITED

REGISTERED NUMBER:06515901

CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2021

	Note	2021 £	As restated 2020 £
Fixed assets			
Tangible assets	5	<u>230,606</u>	<u>339,496</u>
		230,606	339,496
Current assets			
Debtors: amounts falling due within one year	7	2,260,692	2,150,897
Bank and cash balances		<u>1,280,183</u>	<u>4,501,382</u>
		3,540,875	6,652,279
Creditors: amounts falling due within one year	8	<u>(8,830,414)</u>	<u>(2,167,333)</u>
Net current (liabilities)/assets		<u>(5,289,539)</u>	<u>4,484,946</u>
Total assets less current liabilities		<u>(5,058,933)</u>	<u>4,824,442</u>
Creditors: amounts falling due after more than one year	9	(251,504)	(4,672,910)
Provisions for liabilities			
Net (liabilities)/assets		<u>(5,310,437)</u>	<u>151,532</u>
Capital and reserves			
Allotted, called up and fully paid		1	1
Share premium account		10,528,601	10,528,601
Foreign exchange reserve		(68,402)	(38,142)
Share based payment reserve		330,568	158,557
Capital redemption reserve		(50,320)	(50,320)
Profit and loss account		<u>(16,050,885)</u>	<u>(10,447,165)</u>
Equity attributable to owners of the parent Company		<u>(5,310,437)</u>	<u>151,532</u>
		<u>(5,310,437)</u>	<u>151,532</u>

MIRADA MEDICAL LIMITED

REGISTERED NUMBER:06515901

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONTINUED) AS AT 31 DECEMBER 2021

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

.....
S G B Jantet

Director

Date: 27 July 2022

The notes on pages 7 to 17 form part of these financial statements.

MIRADA MEDICAL LIMITED
REGISTERED NUMBER:06515901

COMPANY STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2021

	Note	2021 £	2020 £
Fixed assets			
Tangible assets	5	206,130	315,267
Investments	6	59,823	59,823
		<u>265,953</u>	<u>375,090</u>
Current assets			
Debtors: amounts falling due within one year	7	5,474,416	4,764,432
Cash at bank and in hand		1,219,578	4,203,941
		<u>6,693,994</u>	<u>8,968,373</u>
Creditors: amounts falling due within one year	8	(7,863,737)	(1,381,768)
Net current (liabilities)/assets		<u>(1,169,743)</u>	<u>7,586,605</u>
Total assets less current liabilities		<u>(903,790)</u>	<u>7,961,695</u>
Creditors: amounts falling due after more than one year	9	(219,961)	(4,672,910)
Net (liabilities)/assets		<u>(1,123,751)</u>	<u>3,288,785</u>
Capital and reserves			
Allotted, called up and fully paid		1	1
Share premium account		10,528,601	10,528,601
Share based payment reserve		330,568	158,557
Profit and loss account brought forward		(7,398,374)	(4,009,875)
Loss for the year		(4,584,547)	(3,388,499)
Profit and loss account carried forward		<u>(11,982,921)</u>	<u>(7,398,374)</u>
		<u>(1,123,751)</u>	<u>3,288,785</u>

MIRADA MEDICAL LIMITED

REGISTERED NUMBER:06515901

COMPANY STATEMENT OF FINANCIAL POSITION (CONTINUED)

AS AT 31 DECEMBER 2021

The Company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the consolidated statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:

.....
S G B Jantet

Director

Date: 27 July 2022

The notes on pages 7 to 17 form part of these financial statements.

MIRADA MEDICAL LIMITED

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2021

	Called up share capital	Share premium account	Share based payment reserve	Foreign exchange reserve	Capital redemption reserve	Profit and loss account	Total equity
	£	£	£	£	£	£	£
At 1 January 2020 (as restated)	1	10,528,601	4,415	(141,082)	(50,320)	(6,400,792)	3,940,823
Loss for the year	-	-	-	-	-	(4,046,373)	(4,046,373)
Foreign exchange movement on subsidiaries	-	-	-	102,940	-	-	102,940
Share based payment charge	-	-	154,142	-	-	-	154,142
At 1 January 2021 (as restated)	<u>1</u>	<u>10,528,601</u>	<u>158,557</u>	<u>(38,142)</u>	<u>(50,320)</u>	<u>(10,447,165)</u>	<u>151,532</u>
Loss for the year	-	-	-	-	-	(5,603,720)	(5,603,720)
Foreign exchange movement on subsidiaries	-	-	-	(30,260)	-	-	(30,260)
Share based payment charge	-	-	172,011	-	-	-	172,011
At 31 December 2021	<u><u>1</u></u>	<u><u>10,528,601</u></u>	<u><u>330,568</u></u>	<u><u>(68,402)</u></u>	<u><u>(50,320)</u></u>	<u><u>(16,050,885)</u></u>	<u><u>(5,310,437)</u></u>

The notes on pages 7 to 17 form part of these financial statements.

MIRADA MEDICAL LIMITED

COMPANY STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 31 DECEMBER 2021

	Called up share capital	Share premium account	Share based payment reserve	Profit and loss account	Total equity
	£	£	£	£	£
At 1 January 2020 (as restated)	1	10,528,601	4,415	(4,009,875)	6,523,142
Loss for the year	-	-	-	(3,388,499)	(3,388,499)
Share based payment charge	-	-	154,142	-	154,142
At 1 January 2021 (as restated)	1	10,528,601	158,557	(7,398,374)	3,288,785
Loss for the year	-	-	-	(4,584,547)	(4,584,547)
Share based payment charge	-	-	172,011	-	172,011
At 31 December 2021	1	10,528,601	330,568	(11,982,921)	(1,123,751)

The notes on pages 7 to 17 form part of these financial statements.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

1. General information

Mirada Medical Limited is a private company limited by shares and incorporated in England and Wales. The address of its registered office and principal place of business is disclosed on the company information page.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The Company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own Statement of Comprehensive Income in these financial statements.

The following principal accounting policies have been applied:

2.2 Basis of consolidation

The consolidated financial statements present the results of the Company and its own subsidiaries ("the Group") as if they form a single entity. Intercompany transactions and balances between group companies are therefore eliminated in full.

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the Statement of Financial Position, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of acquired operations are included in the Consolidated Statement of Comprehensive Income from the date on which control is obtained. They are deconsolidated from the date control ceases.

In accordance with the transitional exemption available in FRS 102, the group has chosen not to retrospectively apply the standard to business combinations that occurred before the date of transition to FRS 102, being 01 January 2015.

2.3 Going concern

The loss for the year reflects the Group's investment in new technology and products. Covid-19 continued to have a negative effect on our ability to sell DLC, our auto contouring software, into Hospitals in some geographies. However the market has started to open up again and existing service and subscription revenue remained robust during 2021 with many customers increasing their subscriptions alongside low churn. 2021 has also seen increased activity with distributors and value-added resellers for our new and existing products, with these partnerships positively affecting the future forecasts.

In March 2021 the Company entered into a £583,402 loan agreement with Innovate UK and secured a £194,273 Paycheck Protection Program loan from the US Small Business Association. The latter was forgiven in August 2021. In April 2022 the Company received additional funding led by Aposite Capital, totalling £5.05M. Due to this being a qualifying event the Future Fund Convertible Loan Note also converted to equity at a value of £6.82M.

The directors have reviewed the future prospects of the Company and prepared a cash flow forecast covering the period until July 2023, taking into account the market and being prudent on the potential impact it may have on the Company's revenue and cashflows. In light of this, the directors have prepared the financial statements on a going concern basis.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.4 Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Group and the revenue can be reliably measured. Revenue is recognised on license delivery and a balance is deferred over the 12-month warranty period.

For subscription licenses revenue is recognised on a monthly basis as the subscription includes both the license and the service element.

Other items such as training, hardware and engineering contracts are recognised when the value is transferred to the customer.

2.5 Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

2.6 Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Long-term leasehold property	-	20%
Office equipment	-	20%
		-33%

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

2.7 Impairment of fixed assets and goodwill

Assets that are subject to depreciation or amortisation are assessed at each reporting date to determine whether there is any indication that the assets are impaired. Where there is any indication that an asset may be impaired, the carrying value of the asset (or cash-generating unit to which the asset has been allocated) is tested for impairment. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's (or CGU's) fair value less costs to sell and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (CGUs). Non-financial assets that have been previously impaired are reviewed at each reporting date to assess whether there is any indication that the impairment losses recognised in prior periods may no longer exist or may have decreased.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.8 Government grants

Grants are accounted under the accruals model as permitted by FRS 102. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the Consolidated Statement of Comprehensive Income in the same period as the related expenditure.

2.9 Financial instruments

The Group only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from other third parties, loans to related parties and investments in ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within one year, typically trade debtors and creditors, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However, if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or in case of an out-right short-term loan that is not at market rate, the financial asset or liability is measured, initially at the present value of future cash flows discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost, unless it qualifies as a loan from a director in the case of a small company, or a public benefit entity concessionary loan.

2.10 Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss except when deferred in other comprehensive income as qualifying cash flow hedges.

Foreign exchange gains and losses that relate to borrowings and cash and cash equivalents are presented in the Consolidated Statement of Comprehensive Income within 'finance income or costs'. All other foreign exchange gains and losses are presented in profit or loss within 'other operating income'.

On consolidation, the results of overseas operations are translated into Sterling at rates approximating to those ruling when the transactions took place. All assets and liabilities of overseas operations are translated at the rate ruling at the reporting date. Exchange differences arising on translating the opening net assets at opening rate and the results of overseas operations at actual rate are recognised in other comprehensive income.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.11 Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

2.12 Pensions

Defined contribution pension plan

The Group operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the Group pays fixed contributions into a separate entity. Once the contributions have been paid the Group has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the Group in independently administered funds.

2.13 Interest income

Interest income is recognised in profit or loss using the effective interest method.

2.14 Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the Company and the Group operate and generate income.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

2. Accounting policies (continued)

2.15 Share based payments

The Group operates an Employee Benefit Trust (EBT) which holds some shares in Mirada Medical Limited. The EBT issues equity-settled share-based options to certain employees in consideration for services to Mirada Medical Limited.

The cost of equity-settled transactions with employees is measured by reference to the fair value at the date at which they are granted and is recognised as an expense over the vesting period which ends on the dates on which the relevant employees become fully entitled to the award. Fair value is determined using a Black-Scholes pricing model. In valuing equity-settled transactions, no account is taken of any vesting conditions other than conditions linked to the price of the shares of the Company (market conditions). No expense is recognised for awards that do not ultimately vest.

At each Statement of Financial Position date before vesting, the cumulative expense is calculated, being the extent to which the vesting period has expired and management's best estimate of the achievement or otherwise of the number of equity instruments that will ultimately vest. The movement in cumulative expense since the previous Statement of Financial Position date is recognised in the Consolidated Statement of Comprehensive Income with a corresponding entry in equity. Where the terms of an equity-settled award are modified or a new award is designated as replacing a cancelled or settled award, the cost based on the original award terms continues to be recognised over the original vesting period. In addition, an expense is recognised over the remainder of the new vesting period for the incremental fair value of any modification, based on the difference between fair value of the original award and the fair value of the modified award, both as measured on the date of the modification, based on the difference between the fair value of the original award and the fair value of the modified award, both as measured on the date of the modification. No reduction is recognised if this difference is negative.

Where an equity-settled award is cancelled, it is treated as if it has vested on the date of cancellation and any cost not yet recognised in the income statement for the award is expensed immediately. Any compensation paid up to the fair value of the award at the cancellation or settlement date is deducted from equity, with any excess over fair value being treated as an expense in the Consolidated Statement of Comprehensive Income.

The share option charge has arisen in respect of share options issued in and awarded to employees of Mirada Medical Limited.

In accordance with FRS 102, paragraph 35.10, section 26 of FRS 102 has not been applied to equity instruments that were granted before the date of transition to this FRS.

2.16 Research and development

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight line basis over their useful economic lives, which range from 3 to 6 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

2.17 Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

3. Employees

The average monthly number of employees, including the directors, during the year was as follows:

	Group 2021 No.	<i>Group 2020 No.</i>	Company 2021 No.	<i>Company 2020 No.</i>
Employees	<u>95</u>	<u>89</u>	<u>81</u>	<u>89</u>

4. Intangible assets

Group and Company

	Goodwill £
Cost	
At 1 January 2021	<u>274,693</u>
At 31 December 2021	<u>274,693</u>
Amortisation	
At 1 January 2021	<u>274,693</u>
At 31 December 2021	<u>274,693</u>
Net book value	
At 31 December 2021	<u>-</u>
<i>At 31 December 2020</i>	<u>-</u>

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

5. Tangible fixed assets

Group

	Long-term leasehold property £	Equipment £	Total £
Cost or valuation			
At 1 January 2021	237,503	714,626	952,129
Additions	-	41,292	41,292
Disposals	-	(310,170)	(310,170)
At 31 December 2021	<u>237,503</u>	<u>445,748</u>	<u>683,251</u>
Depreciation			
At 1 January 2021	69,668	542,965	612,633
Charge for the year on owned assets	47,501	102,681	150,182
Disposals	-	(310,170)	(310,170)
At 31 December 2021	<u>117,169</u>	<u>335,476</u>	<u>452,645</u>
Net book value			
At 31 December 2021	<u>120,334</u>	<u>110,272</u>	<u>230,606</u>
<i>At 31 December 2020</i>	<u>167,835</u>	<u>171,661</u>	<u>339,496</u>

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

5. Tangible fixed assets (continued)

Company

	Long-term leasehold property	Office equipment	Total
	£	£	£
Cost or valuation			
At 1 January 2021	237,503	606,247	843,750
Additions	-	23,143	23,143
Disposals	-	(310,170)	(310,170)
At 31 December 2021	<u>237,503</u>	<u>319,220</u>	<u>556,723</u>
Depreciation			
At 1 January 2021	69,668	458,815	528,483
Charge for the year on owned assets	47,501	84,779	132,280
Disposals	-	(310,170)	(310,170)
At 31 December 2021	<u>117,169</u>	<u>233,424</u>	<u>350,593</u>
Net book value			
At 31 December 2021	<u>120,334</u>	<u>85,796</u>	<u>206,130</u>
At 31 December 2020	<u>167,835</u>	<u>147,432</u>	<u>315,267</u>

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

6. Fixed asset investments

Company

Investments in
subsidiary
companies
£

Cost or valuation

At 1 January 2021 and 31 December 2021

59,823

Subsidiary undertakings

The following were subsidiary undertakings of the Company:

Name	Registered office	Class of shares	Holding
Mirada Medical USA, Inc	1630 Welton Street, Suite 200 D, Denver, Colorado 80202, USA	Ordinary	100 %
Mirada Medical (EBT) Limited	New Barclay House, 234 Botley Road, Oxford, Oxfordshire, England, OX2 0HP	Ordinary	100 %
Mirada Medical Europe SAS	31 Rue d'Armagnac Ilot Quai 8.2, Batiment E1 Bordeaux 33800, France	Ordinary	100 %

7. Debtors

	Group 2021 £	Group 2020 £	Company 2021 £	Company 2020 £
Trade debtors	955,534	969,752	548,425	519,057
Amounts owed by group undertakings	-	-	3,643,826	3,053,064
Other debtors	138,799	101,294	179,597	143,067
Prepayments and accrued income	386,504	349,111	322,713	318,504
Tax recoverable	779,855	730,740	779,855	730,740
	<u>2,260,692</u>	<u>2,150,897</u>	<u>5,474,416</u>	<u>4,764,432</u>

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

8. Creditors: Amounts falling due within one year

	Group	<i>Group As restated</i>	Company	<i>Company As restated</i>
	2021	<i>2020</i>	2021	<i>2020</i>
	£	<i>£</i>	£	<i>£</i>
Trade creditors	243,223	<i>154,296</i>	228,250	<i>150,293</i>
Other taxation and social security	129,533	<i>134,035</i>	127,946	<i>126,188</i>
Other creditors	6,627,827	<i>18,309</i>	6,627,212	<i>18,309</i>
Accruals and deferred income	1,829,831	<i>1,860,693</i>	880,329	<i>1,086,978</i>
	<u>8,830,414</u>	<i><u>2,167,333</u></i>	<u>7,863,737</u>	<i><u>1,381,768</u></i>

Other creditors due in more than one year relate to Future Funds, with a maturity date of 36 months from inception in July 2020. The future fund loan is a potentially convertible loan which could convert into a variable number of shares and as a result is non-basic financial instrument. In line with the accounting policy 2.9, the instrument is therefore disclosed entirely as a liability and is carried at fair value at each reporting date.

The Directors undertook a fair value exercise at the at the year end. The difference in the fair value has resulted in a loss of £1,933,983 (2020 - £324,625), which has been recognised in the profit and loss for the year.

The key assumptions within the model include the expected repayment or conversion date, the likelihood of such events taking place and projections around the growth of the business. Any change in these assumptions would result in a change in the carrying value of the instrument at each reporting date.

9. Creditors: Amounts falling due after more than one year

	Group	<i>Group As restated</i>	Company	<i>Company As restated</i>
	2021	<i>2020</i>	2021	<i>2020</i>
	£	<i>£</i>	£	<i>£</i>
Other creditors	-	<i>4,384,625</i>	-	<i>4,384,625</i>
Accruals and deferred income	251,504	<i>288,285</i>	219,961	<i>288,285</i>
	<u>251,504</u>	<i><u>4,672,910</u></i>	<u>219,961</u>	<i><u>4,672,910</u></i>

10. Commitments under operating leases

At 31 December 2021 the Group and the Company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

	Group	<i>Group 2020</i>	Company	<i>Company 2020</i>
	£	<i>£</i>	£	<i>£</i>
Not later than 1 year	155,903	<i>155,903</i>	155,903	<i>155,903</i>
Later than 1 year and not later than 5 years	223,028	<i>378,931</i>	223,028	<i>378,931</i>
	<u>378,931</u>	<i><u>534,834</u></i>	<u>378,931</u>	<i><u>534,834</u></i>

MIRADA MEDICAL LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2021

11. Prior year adjustment

The comparative year figures have been restated to reclassify £1,860,693 (Company - £1,086,978) from accruals and deferred income due in more than 1 year as a current liability, as these were due in less than 1 year from 31 December 2020. This had no effect on Group or Company reserves as at 1 January 2021.

In addition, a restatement to the consolidated profit and loss reserves to show a foreign exchange reserve and share option reserve was made to reclassify the foreign exchange movements on the overseas subsidiaries and share based payment charge in a separate reserve.

This had no effect on the Group or Company reserves.

12. Related party transactions

Purchases of £Nil were made from Albion Capital in the year (2020: £15,061), to whom £Nil was owed at year end (2020: £11,250). The Directors consider Albion to be a related party due to the influence of Mr D Gudgin over its affairs.

No revenue was recognised from MedyMatch Technology Ltd (now operating under MaxQ Ltd) in the year (2020: £Nil). A balance of £Nil was owing at year end (2020: £69,308). The directors consider MaxQ Ltd to be a related party due to the influence of Mr E Saragnese over its affairs. From 1st January 2021 MaxQ Ltd is not considered a related party as Mr E Saragnese no longer has influence over its affairs.

Purchases of £Nil were made from Apposite in the year (2020: £15,216), to whom £Nil was owed at year end (2020: £11,250). The Directors consider Apposite to be a related party due to the influence of Mr S Gray over its affairs.

Purchases of £64,375 were made from Cior Consulting in the year (2020: £103,863), to whom £Nil was owed at the year end (2020: £Nil), which the directors consider to be a related party due to the influence of Mr D Lawrence over its affairs.

There are no other related parties which require disclosure in accordance with Financial Reporting Standard 102.

13. Post balance sheet events

In April 2022 the Company received additional funding lead by Apposite Capital, totalling £5.05M. Due to this being a qualifying event the Future Fund Convertible Loan Note also converted to equity at a value of £6.82M.

14. Auditor's information

The auditor's report on the financial statements for the year ended 31 December 2021 was unqualified.

The audit report was signed on 28 July 2022 by Tom Woods ACA (Senior Statutory Auditor) on behalf of Menzies LLP.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.